Nonpeptide thrombopoietin receptor (TPOR/MPL) agonists, such as eltrombopag, have been used to treat thrombocytopenia of various aetiologies. Here, we investi- 
interaction of TPO with its receptor induces transphosphorylation and activation of two Janus kinases, JAK2 and TYK2, which in turn results in the activation of signal transducer and activator of transcription 5 (STAT5), phosphoinositide-3 kinase (PI3K) and mitogenactivated protein kinase (MAPK), [8] [9] [10] thereby stimulating megakaryocyte duplication and differentiation into platelets. Genetic elimination of TPO or TPOR in mice reduces the number of bone marrow megakaryocytes and circulating platelets by 80%-90%, 11, 12 suggesting that the TPO/TPOR signalling pathway is critical for maintaining the normal number of platelets in vivo. Thus, TPOR is recognized as an ideal target for the treatment of thrombocytopenia.
First-generation TPOR agonists, such as recombinant human TPO (rhTPO) and PEGylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF), have demonstrated efficacy in increasing platelet counts in the clinic. 5 However, patients treated with these agonists often develop autoantibodies that crossreact with and neutralize endogenous TPO, subsequently leading to severe thrombocytopenia or pancytopenia. 5, 13 Thus, there is a need for drugs that are not structurally similar to TPO, and thus avoid immunogenic responses against the endogenous TPO, but are able to stimulate TPOR. 13, 14 Second-generation agents include peptide agents and nonpeptide compounds. To date, two different thrombopoietic drugs-romiplostim, a peptide compound, and eltrombopag, a nonpeptide TPOR agonist-have been approved for clinical use. [14] [15] [16] Potential advantages of small-molecule mimetics include their putative lack of immunogenicity, nonparenteral route of administration, as well as their lower costs of production. However, it has been reported that eltrombopag requires high daily dosing because of its low activity; this drug also comes with a black box warning for potential hepatotoxicity, with elevated liver enzyme levels or clinical signs of liver damage. [17] [18] [19] These observations highlight the desirability of developing small-molecule TPOR agonists with improved efficacy and reduced toxicity.
Here, employing proliferation assays using human TPOR-transfected murine 32D cells (32D-MPL), we demonstrated that hetrombopag ( Figure 1A ) is a novel, active, small-molecule TPOR agonist.
Compared with eltrombopag, hetrombopag, which is currently in Phase 3 clinical trials in China, more potently stimulated TPORdependent signal transduction, promoted cell viability and/or differentiation, and prevented apoptosis in TPOR-positive cells. Importantly, hetrombopag specifically enhanced the viability and promoted the growth of 32D-MPL cells in hollow fibres implanted in nude mice, exhibiting much higher potency than eltrombopag in vivo.
| MATERIALS AND METHODS

| Materials
Hetrombopag, provided by Jiangsu Hengrui Medicine Co. Ltd.
(Jiangsu, China), was prepared as 10 mmol/L stock solutions in dimethylsulphoxide for in vitro studies or in 0.5% carboxymethylcellulose containing 0.1% Tween-80 for in vivo studies. Eltrombopag was purchased from Selleckchem (Houston, TX). 
| Cell culture
The murine myeloid 32D cell line was obtained from American Type 
| Western blotting
Cells were cytokine-starved overnight and treated with different , recombinant human TPO (rhTPO) and recombinant human erythropoietin (rhEPO) were used as controls. Results were representative of at least three independent experiments and were expressed as means ± SD. C, Effects of different stimuli on TPOR-dependent signal transduction in 32D-MPL cells. 32D-MPL cells were treated with 30 nmol/L hetrombopag, 1000 nmol/L eltrombopag, 100 ng/mL rhTPO, 20 ng/mL recombinant human granulocyte colony-stimulating factor (rhGCSF), or 100 IU/mL rhEPO for 30 minutes. D, 32D-MPL cells were treated with increasing concentrations of hetrombopag, eltrombopag or rhTPO (100 ng/mL) for 30 minutes. E, 32D-MPL cells were treated with hetrombopag (10 nmol/L), eltrombopag (100 nmol/L) or rhTPO (10 ng/ mL) for the indicated time. Whole-cell lysates were analysed by Western blotting using the indicated antibodies secondary antibodies. Proteins were detected by immunoblotting using a Western blot imaging system (Clinx Science Instruments, Shanghai, China).
| Flow cytometry analysis
Flow cytometry analyses were used to investigate the cell cycle and apoptosis, as described previously. 20 
| Cell differentiation assay
Human CD34 + cells were plated in IMDM containing 20% FBS and 100 ng/mL rhSCF and then treated with rhTPO or compounds for 10 days. Cells were stained with anti-human CD41-FITC, isotype control antibody, or PBS (autofluorescence control). Flow cytometric analyses were performed using a FACScan flow cytometer (BD Biosciences).
Gates for CD41 + cells were based on the negative control (ie, SCF-treated cultures). Data were presented as a percentage, calculated as follows: TPO max = (% CD41 sample − % CD41 SCF )/(% CD41 TPO − % CD41 SCF ). Cells which were stained with both anti-human CD41-FITC and CD42a-PE represented mature MK (CD41 + /CD42a + cells).
| Megakaryocyte proplatelet formation
The megakaryocyte proplatelet formation was conducted as described previously. 21 Human CB CD34 + cells were cultured with hetrombopag, eltrombopag or rhTPO to stimulate MK differentiation.
At day 14, the proplatelet-bearing MK were counted using a Leica DMIRB inverted light microscope (Leica Microsystems, Australia). In addition, the number of CD41 + cells was determined by flow cytometry. The number of proplatelet-bearing MK was determined as (proplatelet-bearing MK/total CD41 + cells)*1000.
| Hollow-fibre assay
All animal experiments were approved by the Institute Animal
Review Board of Shanghai Institute of Materia Medica, Chinese
Academy of Sciences, with firm adherence to ethical guidelines for the care and use of animals.
In vivo hollow-fibre assays were performed as described previously. 22 Briefly, a hollow fibre was filled with the cell suspension
(1 × 10 7 cells/mL) and subsequently sealed in 2-cm segments. The hollow-fibre capsules were inserted into subcutaneous tissue through a 10-gauge trocar, after which mice were randomly assigned to control and treatment groups. Control groups were given vehicle alone, and treatment groups received oral hetrombopag or eltrombopag. Mice were sacrificed at the end of treatment, and the subcutaneously implanted cells were collected in culture medium and subjected to MTT assays.
Pharmacokinetics/pharmacodynamics studies were carried out as described previously. 23 Mice implanted with 32D-MPL cell-containing hollow fibres received a single dose of 18 mg/kg hetrombopag or vehicle; 32D-MPL hollow fibres and blood were collected at different times postdosing. Concentrations of hetrombopag in plasma were determined by HPLC/tandem mass spectrometry. Cells in hollow fibres were subjected to MTT assay or Western blot analysis.
| Statistics
Data are presented as means ± SD (in vitro) or means ± SEM (in vivo), and significance was assessed with Student's t test. Differences were considered significant at P < 0.05.
| RESULTS
| Hetrombopag is a nonpeptide agonist of human TPOR
Screening of a chemical compound series by proliferation assays using 32D cells stably transfected with human TPOR (32D-MPL) led to our identification of the TPOR agonist hetrombopag ( Figure 1A ).
The proliferation-stimulating activity of this compound towards 32D- Thrombopoietin (TPO) acts through binding to TPOR to stimulate multiple intracellular signalling pathways, including JAK/STAT, PI3K/ AKT and ERK1/2. [8] [9] [10] To elucidate the molecular mechanisms by which hetrombopag promoted proliferation, we examined whether hetrombopag activated these intracellular signalling pathways in 32D-MPL cells. Control experiments confirmed that the cytokines rhGCSF or rhEPO had no effect on TPO/TPOR signalling-dependent phosphorylation of these targets ( Figure 1C ). Similar to rhTPO, both hetrombopag and eltrombopag induced phosphorylation of the major components of TPO-mediated signalling, including STAT3, STAT5, ERK1/2, and AKT ( Figure 1C ). Furthermore, hetrombopag stimulated the phosphorylation of these TPOR downstream effectors in a concentration-dependent manner ( Figure 1D ). In keeping with its proliferation-stimulating activity, hetrombopag exerted much stronger stimulation of TPO/TPOR signalling in 32D-MPL cells than did eltrombopag ( Figure 1D ). Further study showed that TPOR downstream effectors peaked at 0.5-2 hours, and decreased to normal level at 12 hours after treatment with rhTPO. However, hetrombopag treatment sustained high levels of signalling for significantly longer periods (0.5-24 hours), and stimulated with eltrombopag, these signalling molecules became maximally active at later timepoints (2-24 hours; Figure 1E ). Taken together, these results indicate that hetrombopag stimulates intracellular TPO signalling pathways and promotes cell proliferation in a TPOR-dependent manner.
| Hetrombopag promotes proliferation and differentiation of human megakaryocyte progenitor cells
Activation of TPOR expressed on the surface of megakaryocytes and their precursors trigger the expression of genes involved in the megakaryocytic pathway and lead to the release of platelets. A previous study showed that the TPOR agonist eltrombopag exerts antiapoptotic activity in TPOR-positive cells. 25 Prolonged withdrawal of cytokines (72 hours) induced apoptosis of 32D-MPL cells, an effect that was reduced by rhTPO, hetrombopag, or eltrombopag ( Figure 3C ). Next, we further elucidated the possible molecular mechanisms underlying this processes. Changing protein expression levels of BCL-2 family members, which are highly dynamically regulated, is a key mechanism for tipping the balance towards or away from apoptotic cell death. 26, 27 Similar to rhTPO, both eltrombopag and hetrombopag increased expression of the antiapoptotic family members BCL-XL and MCL-1, and decreased expression of pro-apoptotic BAK ( Figure 3D ). Furthermore, the antiapoptotic action of hetrombopag was prevented by ABT-737, a BCL-2/BCL-XL inhibitor ( Figure 3E ). These results demonstrate for the first time that TPOR agonists drive appropriate cell cycling of 32D-MPL cells through upregulation of G 1 -phase-related regulatory proteins, and prevent apoptosis through alterations in BCL-XL/BAK expression.
| Additive effect of hetrombopag in combination with rhTPO
A previous study showed that effects of eltrombopag and rhTPO in TPOR-positive cell lines were additive. 25 Accordingly, we investigated whether this was also the case for hetrombopag. As shown in 
| Analysis of the pharmacodynamics and pharmacokinetics of hetrombopag using hollow-fibre assay
Our previous study showed that hollow-fibre assay using 32D-MPL cells is a specific and efficient approach for rapidly evaluating the in vivo activity of small-molecule TPOR agonists. 22 Here, we used this assay to evaluate the pharmacodynamics of hetrombopag on the TPOR-dependent signalling pathway and its relationship to the pharmacokinetics of hetrombopag. After oral administration of a single 18-mg/kg dose of hetrombopag, the plasma concentration of hetrombopag peaked at 687 ± 342 ng/mL at 3 hours and decreased to 4.5 ± 0.5 ng/mL at 24 hours ( Figure 5A ). In association with these changes, the phosphorylation of STAT3, STAT5 and ERK1/2 was first detected at 3 hours, peaked at 6-12 hours, and lasted about 24 hours ( Figure 5B ).
We next examined the effect of administration of a single oral 18-mg/kg dose of hetrombopag on cell viability over the course of 
| In vivo activity of hetrombopag in hollowfibre assay
On the basis of pharmacodynamic/pharmacokinetic studies of hetrombopag using hollow-fibre assay, we used a once-daily dosing regimen in nude mice subcutaneously implanted with hollow fibres | 5373 hollow fibres in the vehicle group after 3 days of treatment (Figure 6A) . These results suggest that daily oral dosing for 3 consecutive days is an optimal schedule. Furthermore, consistent with in vitro results, daily oral administration of hetrombopag for 3 consecutive days showed greater efficacy in stimulating the in vivo proliferation of 32D-MPL cells than eltrombopag ( Figure 6B ). The in vivo efficacy of hetrombopag was also dose-dependent, and was significant at doses of 6 mg/kg or greater (P < 0.01).
Further study showed that neither hetrombopag nor eltrombopag had an effect on the in vivo proliferation of TPOR-negative 32D-Vector cells in hollow fibres ( Figure 6C ). Furthermore, hetrombopag had no effect on the counts of white blood cells, reticulocytes, or platelets in the peripheral blood of mice ( Figure 6D ). Taken together, the in vivo results obtained by hollow-fibre assay indicate that orally administered hetrombopag specifically activates human TPOR signalling and is more efficacious than eltrombopag.
| DISCUSSION
The TPO/TPOR signalling pathway plays a central role in regulating both megakaryopoiesis and platelet production. Thus, the use of TPOR agonists represents a major approach for the treatment of thrombocytopenia. 28 Among these agonists, nonpeptide agonists of TPOR, such as eltrombopag, butyzamide and NIP-004, have advantages over peptide agonists in that they are orally bioavailable and are unlikely to induce an immune response. 25, 29, 30 Here, we identified hetrombopag, a member of the biarylhydrazone class of compounds, as a novel, orally active TPOR agonist. Hetrombopag was capable of activating TPO-specific signal transduction, stimulating proliferation and differentiation, and preventing apoptosis in TPOR-positive cells. Importantly, hetrombopag exhibited greater efficacy than eltrombopag both in vitro and in vivo, and exerted effects that were additive with those of rhTPO.
TPOR belongs to the type I cytokine receptor family, which includes EPOR and GCSF receptors. Like EPOR and GCSF receptors, this homodimeric receptor undergoes a major conformational change upon agonist binding, followed by phosphorylation of its intracellular domain and various secondary signalling molecules. 6 Although numerous growth factors had been shown to stimulate platelet production, the extent to which platelet count increases is of marginal clinical significance. 31 Our study showed that neither rhGCSF nor TPO/TPOR signalling is able to inactivate or induce more than 100
proteins, and generally exerts a prosurvival effect. 32 For the first time,
we found that TPOR agonists, including hetrombopag and eltrombopag, as well as rhTPO, effectively up-regulated the G 1 -phase-related proteins p-RB, Cyclin D1 and CDK4/6, and normalized the cell-cycle profile in 32D-MPL cells. To the best of our knowledge, these interesting effects on cell cycling revealed by our investigation of hetrombopag have not been investigated in previous studies on TPOR agonists. A previous study showed that TPOR agonists affect the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. 32 TPOR agonists have also been reported to exert antiapoptotic activity in TPOR-positive cells. 25 Here, hetrombopag suppressed caspase and poly-(ADP-ribose) polymerase (PARP) cleavage (data not shown) and prevented apoptosis of 32D-MPL cells. In addition, hetrombopag-stimulated AKT signalling, which has been shown to inhibit apoptosis through regulation of BCL-2 family proteins. 33 Consistent with these reports, we found that hetrombopag-stimulated BCL-XL and MCL-1 expression, and inhibited BAK expression.
Furthermore, the antiapoptotic effect of hetrombopag was prevented by the BCL-2/BCL-XL inhibitor ABT-737, confirming that hetrombopag attenuates apoptosis through modulation of BCL-XL/BAK.
Romiplostim is thought to bind directly to the TPO-binding site on TPOR, whereas eltrombopag has been proposed to bind to TPOR near its membrane insertion site, away from the active site. Notably, published animal data on nonpeptide agonists such as eltrombopag are often limited because such agents are only active in humans and chimpanzees. 25, 29, 30 The hollow-fibre assay is currently in routine use as a screening tool for anticancer drug discovery. 35 Our previous study showed that the 32D-MPL hollow-fibre assay was a specific and efficient model for rapidly evaluating the in vivo activity of smallmolecule TPOR agonists. 22 Here, this assay was used to investigate the pharmacokinetic and pharmacodynamic characteristics of hetrom- reported in a clinical study. 36 However, double-peaks of plasma concentrations were not observed at the time-points used in our experimental paradigm. Our pharmacodynamic and pharmacokinetic data for hetrombopag based on hollow-fibre assays indicated that a once-daily dosing regimen would be appropriate for clinical use, a finding that is generally consistent with the results of a Phase 1 study. 36 In vivo hollow-fibre assay results indicated that oral doses of hetrombopag of 6 mg/kg and above were effective, as measured by bopag. Low doses of hetrombopag that achieve a comparable pharmacological effect might also reduce the potential for off-target toxicity.
In a previous eltrombopag study, aminotransferase was found to be elevated by 2%-4%, and treatment was interrupted in several subjects owing to liver toxicity, 18 but no preclinically or clinically significant abnormalities in hepatobiliary laboratory tests were found. 36 In conclusion, we identified the nonpeptide, hetrombopag, as a TPOR agonist, and showed that it mimicked, and was additive with, the biological activity of TPO. Moreover, hetrombopag exhibited greater pharmacological efficacy than eltrombopag both in vitro and in vivo. These preclinical results provide the foundation for clinical evaluations of hetrombopag for treating thrombocytopenia of various aetiologies.
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